Iron Home > Curriculum > Curriculum 5 > Cerebral Infarcts in Patients with Sickle Cell Disease
Cerebral Infarcts in Patients with Sickle Cell Disease
Join Miguel R. Abboud, MD, for this webcast, âCerebral Infarcts in Patients with Sickle Cell Disease,â in which he discusses the role of transfusion in primary and secondary stroke prevention in patients with sickle cell disease. He will also present recent data on the efficacy of chronic transfusions to prevent the development of silent infarcts. Chelation therapy remains the standard of care to prevent iron overload in patients with chronic transfusions, and distinctions between available agents will be reviewed.
Target AudienceThis activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
- Assess the classifications and epidemiology of cerebral infarcts in patients with
sickle cell disease in order to identify at-risk patients who would benefit from blood transfusion.
- Evaluate the efficacy and safety profiles of currently available iron chelators and integrate these agents into treatment and monitoring strategies for patients with sickle cell disease who are receiving transfusion in order to prevent complications of iron overload.
||Miguel R. Abboud, MD
Professor of Pediatrics
Chairman, Department of Pediatrics and Adolescent Medicine
American University of Beirut Medical Center
|Miguel R. Abboud, MD
has received salary/honoraria from Novartis Pharmaceuticals Corporation and royalty payments from New England Journal of Medicine.
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
1 avenue Claude Vellefaux.
75475 Paris Cedex 10, France
All Rights Reserved
Copyright ESH 2020